Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

163.45 +0.62 (+0.38%)
Official Closing Price Updated: 7:00 PM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,680,615
Open 162.32
Bid (Size) 163.25 (5)
Ask (Size) 164.00 (1)
Prev. Close 162.83
Today's Range 161.90 - 163.73
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
The DOJ's U.S. Trustee Program seeks to dismiss Johnson & Johnson's third attempt to settle 60,000 talc lawsuits via bankruptcy, arguing the filing is a bad-faith strategy to avoid liability. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Peering Into Johnson & Johnson's Recent Short Interest
Via Benzinga

Performance

YTD
+2.18%
+2.18%
1 Month
+0.14%
+0.14%
3 Month
+7.29%
+7.29%
6 Month
+9.29%
+9.29%
1 Year
+7.97%
+7.97%

More News

Read More
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Via Investor's Business Daily
What's Going On With Kenvue Stock Monday?
Via Benzinga
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson Unusual Options Activity
Via Benzinga
Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump
Via Talk Markets
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
Via Benzinga
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
Via The Motley Fool
Topics Stocks
Exposures US Equities
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Three Safe Dividend Kings to Weather Any Storm
Via Talk Markets
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
Via Benzinga
Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
Via The Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
Via The Motley Fool
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Via Benzinga
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Via The Motley Fool
Are JNJ’s Mergers And Acquisitions Weighing Down Company’s Performance?
Via Talk Markets
Cancer Drugs Propel J&J Beyond Wall Street Estimates
Via Benzinga
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
Via Benzinga
Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?
Via Benzinga
Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.